MM
MM3.F Merit Medical Systems Inc
- Market cap
- EUR 4.73B
- P/E
- 34.3x
- P/B
- 2.99x
- ROE
- 9.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MM3.F undervalued?
Graham numberMM3.F trades 113.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merit Medical Systems Inc fundamental analysis
No fundamental analysis for Merit Medical Systems Inc yet.
Merit Medical Systems Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merit Medical Systems Inc
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, …
Full company profileMerit Medical Systems Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merit Medical Systems Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 604M | 728M | 883M | 995M | 964M | 1.07B | 1.15B | 1.26B | 1.36B | 1.52B | 1.62B |
| Gross Profit | 265M | 326M | 395M | 432M | 401M | 485M | 519M | 584M | 643M | 738M | 801M |
| Operating Income | 35.4M | 45.7M | 59.2M | 39.5M | 45.9M | 78.4M | 94.4M | 127M | 156M | 186M | 218M |
| EBITDA | - | 97.2M | 129M | 119M | 104M | 155M | 181M | 229M | 296M | 332M | 385M |
| Net Income | 20.1M | 27.5M | 42.0M | 5.45M | -9.84M | 48.5M | 74.5M | 94.4M | 120M | 128M | 163M |
| EPS | - | 0.55 | 0.77 | 0.10 | -0.18 | 0.86 | 1.30 | 1.63 | 2.05 | 2.16 | 2.72 |
| Balance Sheet | |||||||||||
| Total Assets | 943M | 1.11B | 1.62B | 1.76B | 1.66B | 1.65B | 1.66B | 2.33B | 2.42B | 2.69B | 2.92B |
| Total Liabilities | 445M | 435M | 687M | 807M | 706M | 608M | 520M | 1.12B | 1.04B | 1.10B | 1.18B |
| Shareholders' Equity | 498M | 676M | 933M | 950M | 959M | 1.04B | 1.14B | 1.20B | 1.38B | 1.58B | 1.74B |
| Cash & Short-term Investments | 19.2M | 32.3M | 67.4M | 44.3M | 56.9M | 67.8M | 58.4M | 587M | 377M | 446M | 504M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 53.6M | 62.7M | 86.5M | 77.8M | 165M | 147M | 114M | 145M | 221M | 297M | 234M |
| Capital Expenditure | 35.1M | 38.6M | 63.3M | 78.2M | 46.0M | 27.9M | 45.0M | 36.7M | 38.0M | 84.8M | 64.0M |
| Free Cash Flow | - | 21.5M | 20.2M | -3.68M | 116M | 119M | 69.3M | 108M | 183M | 213M | 170M |
| Ratios | |||||||||||
| ROE | 4.0% | 4.1% | 4.5% | 0.6% | -1.0% | 4.7% | 6.5% | 7.9% | 8.7% | 8.1% | 9.3% |
| ROA | 2.1% | 2.5% | 2.6% | 0.3% | -0.6% | 2.9% | 4.5% | 4.1% | 5.0% | 4.8% | 5.6% |
| Net Profit Margin | 3.3% | 3.8% | 4.8% | 0.5% | -1.0% | 4.5% | 6.5% | 7.5% | 8.9% | 8.5% | 10.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Merit Medical Systems Inc dividends
Merit Medical Systems Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 5:4 on May 6, 2011.
Who owns Merit Medical Systems Inc
- Insiders 2.44%
- Institutions 97.56%
- Public & others 0.00%
- Shares outstanding 59.9M
- Free float 58.5M
Merit Medical Systems Inc company profile
- Company name
- Merit Medical Systems Inc
- Ticker
- MM3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 7,500
- Fiscal year end
- December
- Address
- 1600 West Merit Parkway, South Jordan, UT, United States, 84095
- Phone
- 801 253 1600
- Website
- merit.com
About Merit Medical Systems Inc
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; kits and accessories for endoscopy and bronchoscopy procedures; and temporary pacing technology. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Merit Medical Systems Inc management
10- Ms. Martha Goldberg AronsonPresident, CEO & Director · born 1967
- Mr. Raul Parra Jr., CPACFO & Treasurer · born 1979
- Mr. Brian G. Lloyd J.D.Chief Legal Officer & Corporate Secretary · born 1961
- Mr. Michel J. VoigtChief Human Resources Officer · born 1973
- Mr. Neil W. PetersonSenior Advisor · born 1966
- Ms. Sheri LewisChief Operations Officer · born 1966
- Ms. Sarah ComstockVice President of Global Communications
- Mr. Ricardo AlvarezManaging Director of Operation Merit Medical Tijuana
- Mr. Mark ButlerExecutive Vice President of Merit Medical EMEA
- Ms. Alisha JerauldSustainability Council Chair and Vice President of Environment, Social & Governance